Analysis of Long‐Term Function and Survival of Edaravone Oral Suspension–Treated Patients With Amyotrophic Lateral Sclerosis Using PRO ‐ ACT Data as Historical Placebo Controls
Muscle & Nerve · 2025
DOI: 10.1002/mus.28462 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Fumihiro Takahashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Edaravone, Free Radical Scavengers, Neuroprotective Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mitsubishi Tanabe Pharma America, Inc..
Abstract (Originalsprache)
Introduction/Aims On/Off dosing of intravenous (IV) edaravone and edaravone oral suspension was US Food and Drug Administration (FDA)‐approved for Amyotrophic Lateral Sclerosis (ALS) treatment. Placebo‐controlled trials showed that IV edaravone slows the rate of physical functional decline in patients with ALS. Here, the impact of edaravone oral suspension on function and survival was assessed.
Methods
Edaravone oral suspension was investigated in clinical trials MT‐1186‐A01/A02/A03/A04. Patients from Studies MT‐1186‐A02/A04 (prespecified analysis) and Studies MT‐1186‐A01/A02/A03/A04 (post hoc analysis) were propensity score matched 1:1 on 10 baseline variables with historical Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) placebo patients (not receiving active investigational treatment in their trials) to assess the impact of edaravone oral suspension on function and survival.
Results
In the prespecified analysis, 78 edaravone oral suspension–treated patients from Studies MT‐1186‐A02/A04 demonstrated a survival benefit versus 78 matched PRO‐ACT placebo patients ( p = 0.005). Baseline risk‐adjusted hazard ratio showed an 84% decreased risk of death in edaravone oral suspension versus PRO‐ACT placebo patients ( p = 0.005). ALS Functional Rating Scale‐Revised (ALSFRS‐R) total score change from baseline at Week 48 was −8.4 points for edaravone oral suspension versus −14.1 points for PRO‐ACT placebo patients ( p < 0.001). In the post hoc analysis, patients from Studies MT‐1186‐A01/A02/A03/A04 ( n = 210) propensity score matched to PRO‐ACT placebo patients ( n = 210) showed statistically significantly longer time to death and smaller ALSFRS‐R change from baseline at Week 48; restricted mean survival time showed a 7.3‐month improvement ( p < 0.001).
Discussion
This suggests edaravone oral suspension significantly increases survival time and decreases physical functional decline versus PRO‐ACT placebo patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.
- Montreal Neurological Institute and Hospital, Montreal, Canada.
- Mitsubishi Tanabe Pharma Europe, Ltd., London, UK.
- NStat Solutions, Biostatistical Services, Rehovot, Israel.
- Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
ORCID-Profile: Stephen Apple
Förderung
- Mitsubishi Tanabe Pharma America, Inc.
Zitieren
APA
Takahashi, F., Genge, A., Hirai, M., Selness, D., Todorovic, V., Wamil, A., Sasson, N., Apple, S., Ushirogawa, Y., & Pooled Resource Open‐Access ALS Clinical Trials Consortium (2025). Analysis of Long‐Term Function and Survival of Edaravone Oral Suspension–Treated Patients With Amyotrophic Lateral Sclerosis Using PRO ‐ ACT Data as Historical Placebo Controls. Muscle & Nerve. https://doi.org/10.1002/mus.28462
Vancouver
Takahashi F, Genge A, Hirai M, Selness D, Todorovic V, Wamil A, et al. Analysis of Long‐Term Function and Survival of Edaravone Oral Suspension–Treated Patients With Amyotrophic Lateral Sclerosis Using PRO ‐ ACT Data as Historical Placebo Controls. Muscle & Nerve. 2025. doi:10.1002/mus.28462
BibTeX
@article{Takahashi2025,
author = {Takahashi, Fumihiro and Genge, Angela and Hirai, Manabu and Selness, Daniel and Todorovic, Vesna and Wamil, Art and Sasson, Nissim and Apple, Stephen and Ushirogawa, Yoshiteru and Pooled Resource Open‐Access ALS Clinical Trials Consortium, Pooled Resource Open‐Access ALS Clinical Trials Consortium},
title = {Analysis of Long‐Term Function and Survival of Edaravone Oral Suspension–Treated Patients With Amyotrophic Lateral Sclerosis Using PRO ‐ ACT Data as Historical Placebo Controls},
journal = {Muscle & Nerve},
year = {2025},
doi = {10.1002/mus.28462}
}
EUVIMED